Virus-like particle (VLP)-based vaccines for pandemic influenza
Open Access
- 13 March 2012
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (3) , 411-414
Abstract
The influenza pandemic of 2009 demonstrated the inability of the established global capacity for egg-based vaccine production technology to provide sufficient vaccine for the population in a timely fashion. Several alternative technologies for developing influenza vaccines have been proposed, among which non-replicating virus-like particles (VLPs) represent an attractive option because of their safety and immunogenic characteristics. VLP vaccines against pandemic influenza have been developed in tobacco plant cells and in Sf9 insect cells infected with baculovirus that expresses protein genes from pandemic influenza strains. These technologies allow rapid and large-scale production of vaccines (3–12 weeks). The 2009 influenza outbreak provided an opportunity for clinical testing of a pandemic influenza VLP vaccine in the midst of the outbreak at its epicenter in Mexico. An influenza A(H1N1)2009 VLP pandemic vaccine (produced in insect cells) was tested in a phase II clinical trial involving 4,563 healthy ...Keywords
This publication has 29 references indexed in Scilit:
- Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine designWIREs Nanomedicine and Nanobiotechnology, 2010
- Human immunodeficiency virus-like particles activate multiple types of immune cellsVirology, 2007
- Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutininVaccine, 2007
- Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenzaVaccine, 2007
- Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza VirusJournal of Virology, 2007
- Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell ResponsesJournal of Virology, 2006
- Vaccine Development for an Imminent Pandemic: Why We Should Worry, What We Must DoHuman Vaccines, 2006
- Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c miceVaccine, 2005
- Virus-Like Particle Vaccine Conferred Complete Protection Against a Lethal Influenza Virus ChallengeViral Immunology, 2005
- Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural ProteinsJournal of Virology, 2001